We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study.
- Authors
Kudaka, Wataru; Nagai, Yutaka; Toita, Takafumi; Inamine, Morihiko; Asato, Kozue; Nakamoto, Tomoko; Wakayama, Akihiko; Ooyama, Takuma; Tokura, Akemi; Murayama, Sadayuki; Aoki, Yoichi
- Abstract
Background: We evaluated the longer-term efficacy and safety of concurrent chemoradiotherapy (CCRT) incorporating high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a lower cumulative radiotherapy (RT) protocol and analyzed prognostic risk factors for survival among patients with FIGO stage III-IVA squamous cell carcinoma (SCC) of the cervix. Patients and methods: Ninety-nine patients with FIGO stage III-IVA SCC of the cervix between 1997 and 2008 were treated with CCRT using cisplatin 20 mg/m for 5 days every 3 weeks or 40 mg/m weekly. Acute and late toxicities were evaluated. Overall survival (OS) and disease-free survival (DFS) were estimated by the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis. Results: Median age was 53.5 years. Median follow-up period was 58 months (range 6-170 months). Pathologically complete response was achieved in 93 patients (96.9 %). The 5-year OS and DFS were 72.0 and 69.3 %, respectively. The 5-year local and distant DFS were 83.0 and 75.1 %, respectively. Thirty-one patients (31.3 %) experienced recurrence. Multivariate analysis showed that tumor size and pretreatment hemoglobin level remained an independent risk factor for OS and DFS. Acute toxicity was moderate. In terms of late adverse effects, 2 patients (2.0 %) suffered from grade 4 late intestinal toxicity because of radiation enterocolitis, with both requiring intestinal surgery. Conclusions: Our study demonstrates that the CCRT schedule in patients with FIGO stage III-IVA SCC is efficacious and safe. In addition, the assessment of tumor size and pretreatment anemia can provide valuable prognostic information.
- Subjects
CANCER treatment; CERVICAL cancer; CANCER chemotherapy; CANCER radiotherapy; RADIOISOTOPE brachytherapy; SQUAMOUS cell carcinoma; FOLLOW-up studies (Medicine); CANCER risk factors
- Publication
International Journal of Clinical Oncology, 2013, Vol 18, Issue 5, p916
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-012-0457-x